Keywordsclinical pharmacology (CPH), CYP2B6, drug abuse, drug-drug interactions, methadone, pharmacokinetics and drug metabolism Methadone is one of the most intensively studied and persistently misunderstood drugs in the contemporary therapeutic armamentarium. First synthesized in the 1930s, it was approved by the US Food and Drug Administration (FDA) in 1947 for analgesic and antitussive use. 1 Subsequently, in the mid-1960s, it was shown to be effective in treating opiate addiction and approved by the FDA in 1972 for this use. Methadone is effective in treating acute and chronic pain, is increasingly used in contemporary anesthesia practice owing to the long duration of effect, 2 is one of the two mainstays in treating opioid addiction, and is a major strategy for HIV/AIDS prevention. Methadone has the longest duration of effect of any approved opioid analgesic. It is used in infants, children, and adults and is administered by oral, intravenous, and other parenteral routes. Methadone is on the World Health Organization's List of Essential Medicines.Methadone was developed and approved long before the regulatory requirements for thorough pharmacokinetic characterizations and myriad in vitro and in vivo preclinical and clinical studies, which are required today for drug approvals. Hence, more than 2 decades ago, investigators began to fill in the missing information. There was reaction phenotyping of methadone metabolism to identify responsible cytochrome P450s (CYPs), and drug-drug interaction studies for both mechanistic discovery and practical clinical considerations. The ensuing evolution of data, concepts, and evidence regarding methadone disposition has been vast. Nevertheless, however, initial concepts and quickly adopted early "common knowledge," as well as practitioner guidelines and regulatory documents, which were later shown to be incorrect, have been remarkably resistant to change.This issue of the Journal of Clinical Pharmacology reports an important retrospective investigation, using the FDA database of drug-drug interaction studies, to provide information on the CYP isoform, which is responsible for methadone metabolism and exposure in humans. 3 The information is mechanistically important, clinically actionable, and relevant for new drug development. The investigators, from the FDA Office of Clinical Pharmacology in the Center for Drug Evaluation and Research, reviewed 29 drugdrug interaction studies between methadone and FDAapproved HIV/hepatitis C virus medications. Subjects in these studies were typically patients receiving daily methadone at steady state, and then the antiviral was introduced. Methadone plasma concentrations, before and after the antiviral, were then determined, either nonselectively or with enantioselective assays. In 16 of the 29 studies, the antivirals caused statistically significant changes in the methadone plasma concentrationtime area under the curve. Methadone exposure was reduced when coadministered with CYP2B6 inducers. In contrast, methadone exposure was either u...